Schonfeld Strategic Advisors LLC Buys New Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Schonfeld Strategic Advisors LLC bought a new stake in shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 46,897 shares of the company’s stock, valued at approximately $150,000. Schonfeld Strategic Advisors LLC owned 0.10% of Checkpoint Therapeutics at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in CKPT. Tower Research Capital LLC TRC grew its position in shares of Checkpoint Therapeutics by 157.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock valued at $34,000 after acquiring an additional 6,486 shares during the period. PUREfi Wealth LLC bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. SBI Securities Co. Ltd. bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Stifel Financial Corp bought a new stake in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Finally, Northern Trust Corp grew its stake in shares of Checkpoint Therapeutics by 16.4% during the 4th quarter. Northern Trust Corp now owns 72,563 shares of the company’s stock valued at $232,000 after acquiring an additional 10,232 shares during the period. 22.00% of the stock is currently owned by institutional investors.

Checkpoint Therapeutics Price Performance

CKPT stock opened at $4.15 on Thursday. Checkpoint Therapeutics, Inc. has a 1-year low of $1.55 and a 1-year high of $4.50. The company has a market capitalization of $347.62 million, a price-to-earnings ratio of -2.26 and a beta of 1.18. The business has a 50 day simple moving average of $4.05 and a two-hundred day simple moving average of $3.62.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Tuesday, May 13th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.09). Sell-side analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CKPT shares. D. Boral Capital reiterated a “buy” rating and set a $4.80 price objective on shares of Checkpoint Therapeutics in a research note on Monday, March 31st. Lake Street Capital reaffirmed a “hold” rating and issued a $4.10 target price (down previously from $7.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $4.10 target price on shares of Checkpoint Therapeutics in a report on Tuesday, March 11th.

Insider Buying and Selling at Checkpoint Therapeutics

In related news, CEO James F. Oliviero III sold 15,090 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total transaction of $60,963.60. Following the completion of the transaction, the chief executive officer now directly owns 3,759,929 shares of the company’s stock, valued at approximately $15,190,113.16. This represents a 0.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William Garrett Gray sold 12,322 shares of the stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $4.05, for a total value of $49,904.10. Following the transaction, the chief financial officer now owns 1,446,322 shares of the company’s stock, valued at $5,857,604.10. This represents a 0.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.10% of the company’s stock.

Checkpoint Therapeutics Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.